vs
Bowhead Specialty Holdings Inc.（BOW）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Bowhead Specialty Holdings Inc.的1.4倍（$207.3M vs $151.7M），Bowhead Specialty Holdings Inc.净利率更高（9.8% vs -62.0%，领先71.8%），Bowhead Specialty Holdings Inc.自由现金流更多（$326.0M vs $-100.8M）
Bowhead Specialty Holdings Inc.是一家专业保险控股企业，主营财产及意外伤害保险产品，聚焦北美地区服务不足的小众细分市场，为商业和个人客户提供定制化风险管理方案与专属保险保障服务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
BOW vs RARE — 直观对比
营收规模更大
RARE
是对方的1.4倍
$151.7M
净利率更高
BOW
高出71.8%
-62.0%
自由现金流更多
BOW
多$426.8M
$-100.8M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $151.7M | $207.3M |
| 净利润 | $14.8M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 11.7% | -54.7% |
| 净利率 | 9.8% | -62.0% |
| 营收同比 | — | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $0.44 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BOWRARE
| Q4 25 | $151.7M | $207.3M | ||
| Q3 25 | $143.9M | $159.9M | ||
| Q2 25 | $133.3M | $166.5M | ||
| Q1 25 | $122.7M | $139.3M | ||
| Q4 24 | — | $164.6M | ||
| Q3 24 | $116.8M | $139.5M | ||
| Q2 24 | $98.9M | $147.0M | ||
| Q1 24 | — | $108.8M |
净利润BOWRARE
| Q4 25 | $14.8M | $-128.6M | ||
| Q3 25 | $15.2M | $-180.4M | ||
| Q2 25 | $12.3M | $-115.0M | ||
| Q1 25 | $11.4M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $12.1M | $-133.5M | ||
| Q2 24 | $5.5M | $-131.6M | ||
| Q1 24 | — | $-170.7M |
营业利润率BOWRARE
| Q4 25 | 11.7% | -54.7% | ||
| Q3 25 | 13.3% | -106.9% | ||
| Q2 25 | 11.9% | -64.8% | ||
| Q1 25 | 11.8% | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | 13.5% | -94.6% | ||
| Q2 24 | 7.5% | -79.1% | ||
| Q1 24 | — | -151.9% |
净利率BOWRARE
| Q4 25 | 9.8% | -62.0% | ||
| Q3 25 | 10.5% | -112.8% | ||
| Q2 25 | 9.3% | -69.0% | ||
| Q1 25 | 9.3% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | 10.4% | -95.7% | ||
| Q2 24 | 5.6% | -89.5% | ||
| Q1 24 | — | -156.8% |
每股收益（稀释后）BOWRARE
| Q4 25 | $0.44 | $-1.28 | ||
| Q3 25 | $0.45 | $-1.81 | ||
| Q2 25 | $0.36 | $-1.17 | ||
| Q1 25 | $0.34 | $-1.57 | ||
| Q4 24 | — | $-1.34 | ||
| Q3 24 | $0.36 | $-1.40 | ||
| Q2 24 | $0.20 | $-1.52 | ||
| Q1 24 | — | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $193.5M | $421.0M |
| 总债务越低越好 | $146.4M | — |
| 股东权益账面价值 | $448.3M | $-80.0M |
| 总资产 | $2.4B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.33× | — |
8季度趋势，按日历期对齐
现金及短期投资BOWRARE
| Q4 25 | $193.5M | $421.0M | ||
| Q3 25 | $197.9M | $202.5M | ||
| Q2 25 | $114.8M | $176.3M | ||
| Q1 25 | $88.0M | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | $132.9M | $150.6M | ||
| Q2 24 | $180.3M | $480.7M | ||
| Q1 24 | — | $112.3M |
总债务BOWRARE
| Q4 25 | $146.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BOWRARE
| Q4 25 | $448.3M | $-80.0M | ||
| Q3 25 | $430.2M | $9.2M | ||
| Q2 25 | $407.2M | $151.3M | ||
| Q1 25 | $391.0M | $144.2M | ||
| Q4 24 | — | $255.0M | ||
| Q3 24 | $364.7M | $346.8M | ||
| Q2 24 | $339.9M | $432.4M | ||
| Q1 24 | — | $140.3M |
总资产BOWRARE
| Q4 25 | $2.4B | $1.5B | ||
| Q3 25 | $2.1B | $1.2B | ||
| Q2 25 | $1.9B | $1.3B | ||
| Q1 25 | $1.8B | $1.3B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.4B | $1.6B | ||
| Q1 24 | — | $1.3B |
负债/权益比BOWRARE
| Q4 25 | 0.33× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $331.6M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $326.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 214.9% | -48.6% |
| 资本支出强度资本支出/营收 | 3.7% | 0.5% |
| 现金转化率经营现金流/净利润 | 22.34× | — |
| 过去12个月自由现金流最近4个季度 | $593.4M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流BOWRARE
| Q4 25 | $331.6M | $-99.8M | ||
| Q3 25 | $114.7M | $-91.4M | ||
| Q2 25 | $109.0M | $-108.3M | ||
| Q1 25 | $47.7M | $-166.5M | ||
| Q4 24 | — | $-79.3M | ||
| Q3 24 | $119.4M | $-67.0M | ||
| Q2 24 | — | $-77.0M | ||
| Q1 24 | — | $-190.7M |
自由现金流BOWRARE
| Q4 25 | $326.0M | $-100.8M | ||
| Q3 25 | $113.5M | $-92.7M | ||
| Q2 25 | $107.4M | $-110.7M | ||
| Q1 25 | $46.5M | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | $118.4M | $-68.6M | ||
| Q2 24 | — | $-79.0M | ||
| Q1 24 | — | $-193.9M |
自由现金流率BOWRARE
| Q4 25 | 214.9% | -48.6% | ||
| Q3 25 | 78.8% | -58.0% | ||
| Q2 25 | 80.6% | -66.5% | ||
| Q1 25 | 37.9% | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | 101.4% | -49.2% | ||
| Q2 24 | — | -53.7% | ||
| Q1 24 | — | -178.2% |
资本支出强度BOWRARE
| Q4 25 | 3.7% | 0.5% | ||
| Q3 25 | 0.9% | 0.8% | ||
| Q2 25 | 1.2% | 1.5% | ||
| Q1 25 | 1.0% | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | 0.9% | 1.2% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 3.0% |
现金转化率BOWRARE
| Q4 25 | 22.34× | — | ||
| Q3 25 | 7.56× | — | ||
| Q2 25 | 8.83× | — | ||
| Q1 25 | 4.18× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 9.88× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BOW
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
